Review of Pharmacoeconomic Studies in Radionuclide Therapy of Painful Bone Metastases
Keywords:
Pharmacoeconomics, Zoledronic acid, Bone metastases, RadiopharmaceuticalAbstract
By virtue of the rapid development of nuclear medicine technologies, pharmacoeconomics shall occupy one of the key roles in assessing the applicability of one or another nuclear medicine’s methods in clinical practice. Based on existing evidence, application of the 153Sm-EDTMP and 89SrCl2 S is an economically feasible approach to treat painful bone metastases. Comparing to existing radiopharmaceutical agents intended for therapy of painful bone metastases, radiopharmaceutical agents that have been developed on the basis of generator-produced radionuclide Rhenium 188 (e.g. 188Re-HEDP, 188Re-zoledronic acid), allow to believe in the explicit economic advantage in future when implementing into clinical practice.Downloads
Published
2017-07-31
Issue
Section
Articles
License
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .